Isobaric terminal labeling tandem mass spectrometric quantification: A high throughput and accurate biomarker screening technique

被引：0
|
作者：
Wang L. [1 ]
Xie L. [1 ]
Lu H. [1 ]
机构：
[1] Department of Chemistry, Institutes of Biomedical Sciences, Fudan University, Shanghai
来源：
Kexue Tongbao/Chinese Science Bulletin | 2016年 / 61卷 / 4-5期
关键词：
Biomarker screening; Isobaric terminal labeling; Mass spectrometry; Quantitative proteomics;
D O I：
10.1360/N972015-00990
中图分类号：
学科分类号：
摘要：
More specific and sensitive biomarkers in early diagnosis and prognosis are required for curing and preventing cancer. Quantitative proteomics methods are widely used in biomarker discovery because of high accuracy, sensitivity and specificity. In the isobaric terminal labeling quantification, peptide terminis are separately derivatized with complementary isotopically labeled reagents. As a result, the peptide gain the same molecular weight in the MS spectrum, and all N- and C-terminal fragment ions will provide quantification data for each peptide throughout the MS/MS spectrum. Because of the simple operation steps, high accuracy and high throughput, such method offers a wide range of ideas for biomarker discovery and screening. We reviewed here all current developed isobaric terminal labeling quantification techniques and their applications in cancer biomarker research. © 2016, Science Press. All right reserved.
引用
收藏
页码：432 / 441
页数：9
相关论文
共 39 条
  • [1] Esserman L.J., Thompson I.M., Reid B., Overdiagnosis and overtreatment in cancer: An opportunity for improvement, Jama, 310, pp. 797-798, (2013)
  • [2] Stewart B.W., Wild C.P., World Cancer Report 2014, (2014)
  • [3] Chen W.Q., Zheng S.R., Zeng H.M., Et al., Report of cancer incidence and mortality in China, 2011, China Cancer, 24, pp. 1-10, (2015)
  • [4] Sawyers C.L., The cancer biomarker problem, Nature, 452, pp. 548-552, (2008)
  • [5] Ludwig J.A., Weinstein J.N., Biomarkers in cancer staging, prognosis and treatment selection, Nat Rev Cancer, 5, pp. 845-856, (2005)
  • [6] Gupta S., Bent S., Kohlwes J., Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C: A systematic review and critical analysis, Ann Intern Med, 139, pp. 46-50, (2003)
  • [7] Wang P., Whiteaker J.R., Paulovich A.G., The evolving role of mass spectrometry in cancer biomarker discovery, Cancer Biol Ther, 8, pp. 1083-1094, (2009)
  • [8] Makawita S., Diamandis E.P., The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: Current strategies for candidate verification, Clin Chem, 56, pp. 212-222, (2010)
  • [9] Simpson R.J., Bernhard O.K., Greening D.W., Et al., Proteomics-driven cancer biomarker discovery: Looking to the future, Curr Opin Chem Biol, 12, pp. 72-77, (2008)
  • [10] Fung E.T., A recipe for proteomics diagnostic test development: The OVA1 test, from biomarker discovery to FDA clearance, Clin Chem, 56, pp. 327-329, (2010)
1234